Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR 0.0088
+0.0002 (2.33%)
Sep 22, 2026, 5:35 PM CET
Fidia Revenue
In the year 2025, Fidia had annual revenue of 29.49M EUR with 39.76% growth. Fidia had revenue of 15.96M in the half year ending December 31, 2025, a decrease of -11.83%.
Revenue
29.49M
Revenue Growth
+9.07%
P/S Ratio
0.14
Revenue / Employee
209.33K
Employees
146
Market Cap
4.39M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.49M | 8.39M | 39.76% |
| Dec 31, 2024 | 21.10M | -9.05M | -30.02% |
| Dec 31, 2023 | 30.15M | 5.54M | 22.52% |
| Dec 31, 2022 | 24.61M | 573.00K | 2.38% |
| Dec 31, 2021 | 24.03M | 2.27M | 10.43% |
| Dec 31, 2020 | 21.76M | -26.24M | -54.66% |
| Dec 31, 2019 | 48.00M | -10.91M | -18.52% |
| Dec 31, 2018 | 58.92M | 10.96M | 22.84% |
| Dec 31, 2017 | 47.96M | -11.66M | -19.56% |
| Dec 31, 2016 | 59.62M | -3.71M | -5.86% |
| Dec 31, 2015 | 63.33M | 6.02M | 10.51% |
| Dec 31, 2014 | 57.31M | 11.53M | 25.18% |
| Dec 31, 2013 | 45.78M | -3.94M | -7.93% |
| Dec 31, 2012 | 49.72M | 4.20M | 9.21% |
| Dec 31, 2011 | 45.53M | -3.24M | -6.64% |
| Dec 31, 2007 | 48.76M | 6.64M | 15.76% |
| Dec 31, 2006 | 42.13M | 7.21M | 20.64% |
| Dec 31, 2005 | 34.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Danieli & C. Officine Meccaniche | 3.94B |
| Biesse | 650.82M |
| SIT S.p.A. | 316.17M |
| Tesmec | 273.24M |
| ILPRA | 86.81M |
| Marzocchi Pompe | 37.47M |
| OSAI Automation System | 34.56M |
| Valtecne | 31.33M |
Fidia News
- 5 hours ago - Eledon Pharmaceuticals (ELDN) Shares Rise on Positive Tegoprubart Trial Data and FDA Fast Track - GuruFocus
- 8 hours ago - Woman held down, force-fed abortion pills at heart of ‘hell on earth’ fight over Biden-era policy - Fox News
- 10 hours ago - Filana Therapeutics (FLNA) Gains FDA Clearance to Resume Epilepsy Trial; Market Pricing ... - GuruFocus
- 10 hours ago - Blood, ketchup-stained ice, fake ghee: FDA suspends licences of 5 Mumbai establishments - The Times of India
- 10 hours ago - Compass Therapeutics (CMPX) Shares Plunge After FDA Calls for Additional Trial; Valuation ... - GuruFocus
- 11 hours ago - Compass Therapeutics (CMPX) Faces FDA Trial Recommendation Amidst Challenging Valuation - GuruFocus
- 11 hours ago - PALI Stock Update: Palisade Bio Gains FDA IND Approval for PALI-2108 Trial - GuruFocus
- 11 hours ago - Quoin Pharmaceuticals (QNRX) Gains FDA Fast Track for QRX003, Faces Valuation Challenges - GuruFocus